Dengue

Dengue

WHO/Fabeha Monir
Jahanara and her child Pavel, who have tested positive for dengue, wait to be admitted to the dengue ward at Mugda Hospital in Dhaka, Bangladesh, on 20 September 2023.

Dengue is the most rapidly expanding mosquito-borne viral disease with an estimated of 5.6 billion people at risk and an increasing public health concern, particularly in tropical and subtropical regions. More than 14 million dengue cases and over 10,000 dengue-related deaths were reported globally in 2024, highlighting the growing public health burden of dengue.

Children are disproportionately affected by severe dengue in many endemic settings and may develop life-threatening complications requiring hospitalization and intensive supportive care. Despite the substantial disease burden, no specific treatments (antiviral and immunomodulators) are currently licensed for dengue, and clinical management relies primarily on fluid management and supportive care. The development of safe and effective therapeutics suitable for children therefore remains an important unmet medical need. New treatments are needed both to reduce progression of non-severe dengue and to improve outcomes in severe disease.

Paediatric Drug Optimization (PADO) for dengue provided an important opportunity to inform the ongoing development of target product profiles (TPPs), ensuring that the specific needs of children are considered early in the development of new dengue therapeutics. Emerging therapeutic pipeline, including direct-acting antivirals, host-directed therapies and monoclonal antibodies, were reviewed to identify priorities for paediatric investigation. The PADO priority list included SII Dengue mAb (formerly VIS513), reflecting its more advanced stage of development and the initiation of clinical studies in children, while the watch list identified other promising candidates for which further investigation, including in paediatric populations, should be encouraged. Particular emphasis was placed on optimizing study designs, endpoints and enrolment strategies to facilitate the inclusion of younger children, particularly those under two years of age, while accounting for age-related differences in clinical presentation and ensuring adequate representation of children and adolescents with relevant comorbidities, including obesity and malnutrition, in clinical trials.

Portfolio products

5 products · PADO-dengue
● Access list: 0    ● Priority list: 1    ● Watch list: 4
0 Access
1 Priority
4 Watch

PADO-dengue priority list 1
SII Dengue mAb (VIS513)
PADO-dengue watch list 4
AV-1
EYU 688
Fenretinide (ISLA-001)
Mosnodenvir (JNJ-1802)

PADO report

Paediatric drug optimization for dengue: meeting report, 23 October 2025
This meeting report summarizes the WHO paediatric drug optimization (PADO) exercise for dengue, convened in October 2025 to identify priorities for the...

Contact

Emmanuel Chanda
Email: chandae@who.int

Afework Hailemariam Tekle
Email: teklea@who.int

Related publications

Target product profiles for treatments for dengue

The increasing global burden and geographic expansion of dengue, coupled with the absence of specific antiviral treatments, underscores the urgent need...

News